RNA Modification in Inflammatory Bowel Diseases

Mika Nakayama; Yuki Ozato; Yoshiko Tsuji; Yasuko Arao; Chihiro Otsuka; Yumiko Hamano; Genzo Sumi; Ken Ofusa; Shizuka Uchida; Andrea Vecchione; Hideshi Ishii

doi:10.3390/biomedicines10071695

Biomedicines (Jul 2022)

RNA Modification in Inflammatory Bowel Diseases

Mika Nakayama,
Yuki Ozato,
Yoshiko Tsuji,
Yasuko Arao,
Chihiro Otsuka,
Yumiko Hamano,
Genzo Sumi,
Ken Ofusa,
Shizuka Uchida,
Andrea Vecchione,
Hideshi Ishii

Affiliations

Mika Nakayama: Department of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
Yuki Ozato: Department of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
Yoshiko Tsuji: Department of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
Yasuko Arao: Department of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
Chihiro Otsuka: Department of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
Yumiko Hamano: Department of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
Genzo Sumi: Department of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
Ken Ofusa: Department of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
Shizuka Uchida: Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Frederikskaj 10B, 2. (Building C), 2450 Copenhagen SV, Denmark
Andrea Vecchione: Department of Clinical and Molecular Medicine, University of Rome “Sapienza,” Santo Andrea Hospital, Via di Grottarossa, 1035-00189 Rome, Italy
Hideshi Ishii: Department of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan

DOI: https://doi.org/10.3390/biomedicines10071695
Journal volume & issue: Vol. 10, no. 7
p. 1695

Abstract

Read online

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder characterized by damage to the intestinal mucosa, which is caused by a combination of factors. These include genetic and epigenetic alterations, environmental influence, microorganism interactions, and immune conditions. Some populations with IBD show a cancer-prone phenotype. Recent studies have provided insight into the involvement of RNA modifications in the specific pathogenesis of IBD through regulation of RNA biology in epithelial and immune cells. Studies of several RNA modification-targeting reagents have shown preferable outcomes in patients with colitis. Here, we note a new awareness of RNA modification in the targeting of IBD and related diseases, which will contribute to early diagnosis, disease monitoring, and possible control by innovative therapeutic approaches.

Published in Biomedicines

ISSN: 2227-9059 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Biology (General)
Website: http://www.mdpi.com/journal/biomedicines

About the journal

Abstract

Keywords